Unknown

Dataset Information

0

Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and resulted in more than 3.3 million deaths, and despite the availability of multiple vaccines, the world still faces many challenges with their rollout. Here, we use the high-density microarray patch (HD-MAP) to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin. We show that the vaccine is thermostable on the patches, with patch delivery enhancing both cellular and antibody immune responses. Elicited antibodies potently neutralize clinically relevant isolates including the Alpha and Beta variants. Last, a single dose of HD-MAP–delivered spike provided complete protection from a lethal virus challenge in an ACE2-transgenic mouse model. Collectively, these data show that HD-MAP delivery of a SARS-CoV-2 vaccine was superior to traditional needle-and-syringe vaccination and may be a significant addition to the ongoing COVID-19 (coronavirus disease 2019) pandemic.

SUBMITTER: McMillan CLD 

PROVIDER: S-EPMC8555896 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and resulted in more than 3.3 million deaths, and despite the availability of multiple vaccines, the world still faces many challenges with their rollout. Here, we use the high-density microarray patch (HD-MAP) to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin. We show that the vaccine is thermostable on the patches, with patch delivery enhancing both cellular and antibody immu  ...[more]

Similar Datasets

Unknown Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
| S-EPMC9291373 | biostudies-literature
Unknown A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
| S-EPMC7745033 | biostudies-literature
Unknown A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies.
| S-EPMC10972590 | biostudies-literature
Unknown A Single-Administration Microneedle Skin Patch for Multi-Burst Release of Vaccine against SARS-CoV-2.
| S-EPMC9874724 | biostudies-literature
Unknown A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.
| S-EPMC8146944 | biostudies-literature
Unknown SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
| S-EPMC7809486 | biostudies-literature
Unknown Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.
| S-EPMC3362687 | biostudies-literature
Unknown A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
| S-EPMC7427994 | biostudies-literature
Unknown SARS-CoV-2 S Omicron Spike B.1.1.529
| EMPIAR-10947 | biostudies-other
Unknown An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission.
| S-EPMC8866462 | biostudies-literature